Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC, a potential new treatment for knee cartilage damage that aims to regenerate damaged tissue rather than simply manage symptoms. The company’s approach comes as researchers at institutions such as Duke University and the Mayo Clinic increasingly focus on restoring damaged cartilage, a tissue with limited blood supply that heals poorly on its own.
Nearly half a million Americans suffer knee cartilage damage each year from long-term wear and everyday accidents. For decades, many available treatments have centered on pain relief and functional restoration, not on replacing damaged cartilage with healthy tissue. GelrinC, an off-the-shelf hydrogel implant, is designed to support the body’s natural cartilage-regeneration process by creating a gradual, controlled repair environment within the damaged area.
Early clinical data for GelrinC has been encouraging, and the product already has approval in Europe. An FDA-authorized pivotal trial is now advancing its development toward potential U.S. approval. If successful, GelrinC could offer a new option for patients seeking to repair cartilage rather than merely manage pain, stiffness, and progressive joint degeneration.
The news matters because cartilage damage often leads to long-term disability and invasive procedures, including knee replacement. A treatment that supports regeneration could reduce the need for such surgeries and improve quality of life for active individuals. The global cartilage repair market is growing, and Regentis is positioning itself in a space where innovation has been limited.
Regentis Biomaterials is traded on the NYSE American under the ticker RGNT. The company’s latest news and updates are available in its newsroom at ibn.fm/RGNT.
The content was disseminated on behalf of Regentis Biomaterials as part of a paid marketing engagement with IBN. According to the disclosure, IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN. Full terms of use and disclaimers are available on the IBN website at https://www.BioMedWire.com/Disclaimer.
InvestorWire, a specialized communications platform focused on wire-grade press release syndication, distributed the announcement. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.InvestorWire.com.
